BREAST CANCER RESEARCH AND SCREENING
New Doubt about Effectiveness of Breast Cancer Screening
A large, almost quarter century long trial, involving 90,000 women, produced no definitive results on any potential benefit of mammograms, thus adding more ammunition to the continuing political and healthcare debate in the U.S. over the ethics and expenses of breast cancer screenings. The study was published on February 11, 2014 in the British Medical Journal. The study used a gold-standard methodology, called the randomized complete design, to assign 44,925 Canadian women of ages 40 to 59 to receive mammograms, while other 44,910 Canadian women received breast exam by themselves alone without mammograms. From the mammogram group, 3,250 women were diagnosed with breast cancer and 500 women had died of the breast cancer. From the non-mammogram group (placebo group), 3,133 women were diagnosed with breast cancer and 505 women had died from the breast cancer. The death rates from both the group are almost same.
Split Opinions Cloud Mammogram Politics
The U.S. Preventive Services Task Force on January 11, 2016 issued a final set of recommendation on mammogram. According to the final recommendation, women between 50 and 74 are recommended to get mammogram every other year. However, the recommendation is at odd with the ones by two other respected medical organizations, namely American Congress of Obstetricians and Gynecologists and American Cancer Society. The American Congress of Obstetricians and Gynecologists recommends regular screening beginning at 40, while American Cancer Society recommends yearly screening starting from the age 45 and then in alternate years beginning at 55.
New Doubt about Effectiveness of Breast Cancer Screening
A large, almost quarter century long trial, involving 90,000 women, produced no definitive results on any potential benefit of mammograms, thus adding more ammunition to the continuing political and healthcare debate in the U.S. over the ethics and expenses of breast cancer screenings. The study was published on February 11, 2014 in the British Medical Journal. The study used a gold-standard methodology, called the randomized complete design, to assign 44,925 Canadian women of ages 40 to 59 to receive mammograms, while other 44,910 Canadian women received breast exam by themselves alone without mammograms. From the mammogram group, 3,250 women were diagnosed with breast cancer and 500 women had died of the breast cancer. From the non-mammogram group (placebo group), 3,133 women were diagnosed with breast cancer and 505 women had died from the breast cancer. The death rates from both the group are almost same.
Split Opinions Cloud Mammogram Politics
The U.S. Preventive Services Task Force on January 11, 2016 issued a final set of recommendation on mammogram. According to the final recommendation, women between 50 and 74 are recommended to get mammogram every other year. However, the recommendation is at odd with the ones by two other respected medical organizations, namely American Congress of Obstetricians and Gynecologists and American Cancer Society. The American Congress of Obstetricians and Gynecologists recommends regular screening beginning at 40, while American Cancer Society recommends yearly screening starting from the age 45 and then in alternate years beginning at 55.
New Methodology to Cut down the Go-to-Market Time
On December 13, 2013, researchers presented an advanced statistical methodology to try out effectiveness of a new breast cancer drug, Veliparib, that would cut down the go-to-market time significantly. Researchers presented their study, dubbed I-SPY 2, at a cancer conference in San Antonio.
Under the study (I-SPY 2), a small group of women was given the experimental drugs or combination, and then given them the surgery. The best result is a complete response, where there is no sign of cancer remains. Each patient's results are analyzed as they come in, and statistical methods are used to compute the probabilities that the drug (Veliparib) would help in various scenarios, depending on which women had complete response. This allows researchers to learn and adapt as study continues, with early patients guiding what treatments later patients get.
I-SPY 2 study suggests that adding chemotherapy drug Carboplatin and Veliparib to the usual chemo before surgery improved outcomes for women with "triple negatives"--breast cancer not fueled by Estrogen, Progestin or the gene that the medicine Herceptin targets.
Veliparib, being made by Abb Vie Inc, a North Chicago-based company, recently spun off from Abbott Laboratory, has now graduated and is eligible for testing in a definitive study.
LUNG CANCER RESEARCH AND SCREENING
Recommendation for Lung Cancer Screening
For the first time, government advisers are recommending lung cancer screening for the people who:
* Are between 55 and 79 years old
* Have smoked a pack of cigarettes a day for 30 years or the equivalent such as 2 packs a day for 15 years
The US Prevention Services Task Force on July 29, 2013 issued recommendation for CT scan for targeted population groups. Public comments will betaken until August 26, 2013.
Under the study (I-SPY 2), a small group of women was given the experimental drugs or combination, and then given them the surgery. The best result is a complete response, where there is no sign of cancer remains. Each patient's results are analyzed as they come in, and statistical methods are used to compute the probabilities that the drug (Veliparib) would help in various scenarios, depending on which women had complete response. This allows researchers to learn and adapt as study continues, with early patients guiding what treatments later patients get.
I-SPY 2 study suggests that adding chemotherapy drug Carboplatin and Veliparib to the usual chemo before surgery improved outcomes for women with "triple negatives"--breast cancer not fueled by Estrogen, Progestin or the gene that the medicine Herceptin targets.
Veliparib, being made by Abb Vie Inc, a North Chicago-based company, recently spun off from Abbott Laboratory, has now graduated and is eligible for testing in a definitive study.
LUNG CANCER RESEARCH AND SCREENING
Recommendation for Lung Cancer Screening
For the first time, government advisers are recommending lung cancer screening for the people who:
* Are between 55 and 79 years old
* Have smoked a pack of cigarettes a day for 30 years or the equivalent such as 2 packs a day for 15 years
The US Prevention Services Task Force on July 29, 2013 issued recommendation for CT scan for targeted population groups. Public comments will betaken until August 26, 2013.